NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring BRAF V600 Mutations
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Children's Oncology Group
You are being asked to participate in this study because you have relapsed or refractory tumor without a proven treatment strategy for cure. The main goal is to test any good and bad effects of the study drug vemurafenib on your tumor. A second goal of the study is to evaluate side effects that might be caused by vemurafenib.